You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Diabetes Articles
Popular Diabetes Articles
Highly Recommended Diabetes Articles
Send a link to this page to your friends and colleagues.
From the Spring Research Guide
Nonalcoholic fatty liver disease (NAFLD) is significantly associated with a moderately increased cardiovascular disease risk among type 2s, according to Italian researchers.
The researchers carried out a study in 2,103 type 2s who were free of diagnosed cardiovascular disease (CVD) at the beginning of the study. During five years of follow-up, 248 participants developed nonfatal coronary heart disease, ischemic stroke or cardiovascular death.
“After adjustment for age, sex, smoking history, diabetes duration, HbA1c, LDL cholesterol, liver enzymes and use of medications, the presence of NAFLD was significantly associated with an increased CVD risk.”
—Diabetes, December 2005
Giovanni Targher, MD, of the Division of Internal Medicine and Diabetes Unity at Sacro Cuore Hospital of Negrar in Verona, Italy, was a lead researcher on the fatty liver study:
What are the symptoms of NAFLD?
Most patients with NAFLD have no symptoms or clinical signs of liver disease at the time of diagnosis, although some patients report fatigue or malaise and a sensation of fullness or discomfort on the right side of the upper abdomen. Hepatomegaly may be the only physical finding in most patients.
Are there any tests that type 2 diabetics can have to detect NAFLD?
The diagnosis of NAFLD in clinical practice, both among nondiabetic subjects and type 2 diabetic patients, can usually be made through medical history, blood testing and imaging studies:
What are some treatment options for people who have NAFLD?
An attempt at gradual weight reduction with appropriate control of plasma glucose and lipid levels (particularly in diabetic patients) is a useful first step. Pharmacologic therapy aimed at the underlying liver disease holds promise. Currently, there are only small pilot studies using insulin-sensitizing oral agents (metformin and glitazones) that have been shown to improve liver function tests as well as histologic findings.
0 comments - Apr 1, 2006
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.